Janux Therapeutics (NASDAQ:JANX) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note issued to investors on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

JANX has been the topic of a number of other reports. Stifel Nicolaus began coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. Scotiabank lowered their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.44.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded down $2.16 during midday trading on Thursday, hitting $48.94. The company had a trading volume of 258,092 shares, compared to its average volume of 709,310. The business’s 50-day simple moving average is $49.61 and its 200-day simple moving average is $46.50. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -43.67 and a beta of 3.52. Janux Therapeutics has a twelve month low of $7.79 and a twelve month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The company’s revenue was down 82.6% on a year-over-year basis. As a group, sell-side analysts forecast that Janux Therapeutics will post -1.34 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. This trade represents a 3.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the stock in a transaction on Friday, October 18th. The shares were purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the acquisition, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 420,610 shares of company stock valued at $19,288,666 in the last 90 days. Company insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Plato Investment Management Ltd raised its position in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank raised its holdings in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Janux Therapeutics in the 2nd quarter valued at $151,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.